Clinical Trials Directory

Trials / Completed

CompletedNCT03920150

Vitamin D 24'000 IU for Oral Intermittent Supplementation

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
58 (actual)
Sponsor
University Hospital, Basel, Switzerland · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Vitamin D deficiency (defined as 25(OH)-vitamin D serum level \<50 nmol/l) is cured with oral supplementation. National guidelines recommend the administration of 800 IU cholecalciferol daily for an effective treatment, especially during the winter (poor sun exposition). Cumulative intermittent administration monthly (24'000 IU) or weekly (5'600 IU) is possible. Commercially available intermittent pharmaceutical forms in Switzerland are liquid (oily or alcoholic solution). The study aims to compare the rise of vitamin D3 levels after treatment between newly developed soft capsules and monthly solution (primary outcome), and to evaluate the effect of a loading dose (without infringing the cumulative maximal dose of 4'000 IU per day) on the achievement of optimal values \>75 nmol/l (secondary outcome). The investigators will use newly developed soft capsules and alcoholic solution, which are commercially available in Switzerland.

Detailed description

Group Control, Alcoholic Drinking Solution: 5 ml of an alcoholic drinking solution with 24'000 IU vitamin D p.o. once a month for 3 months (3 doses). Group IMP, Capsules: one capsule with 24'000 IU vitamin D p.o. once a month for 3 months (3 doses). Group IMP + loading dose, Loading Dose: one capsule with 24'000 IU vitamin D p.o. once a week during an individually calculated number of weeks. All 3 groups: Measurement of vitamin D in serum before therapy and one week after the last dose.

Conditions

Interventions

TypeNameDescription
DRUGVitamin D3Patient will be treated with 3 doses of alcoholic solution for 3 months.
DRUGVitamin D oily capsulesPatient will be treated with 3 capsules for 3 months.
DRUGVitamin D oily capsulesPatient will be treated with weekly capsules for an individually calculated number of weeks.

Timeline

Start date
2019-09-30
Primary completion
2020-05-31
Completion
2020-05-31
First posted
2019-04-18
Last updated
2020-06-04

Locations

1 site across 1 country: Switzerland

Source: ClinicalTrials.gov record NCT03920150. Inclusion in this directory is not an endorsement.